# OnCo record merkel-cell-carcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/merkel-cell-carcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "merkel-cell-carcinoma" ;
  schema:name "Merkel cell carcinoma"@en ;
  schema:description "Merkel cell carcinoma is a rare, fast-growing skin cancer, usually caused by a common virus (Merkel cell polyomavirus) or by sun damage. It was almost untreatable once it spread; PD-1/PD-L1 immunotherapy now gives lasting responses in about half of patients."@en ;
  schema:url <https://onco.cc/cancers/merkel-cell-carcinoma/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Merkel-cell_carcinoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1711744> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1444>, <https://merkelcell.org/>, <https://www.cancer.gov/types/skin/patient/merkel-cell-treatment-pdq> ;
  onco:tag "gap-fill", "skin", "rare" ;
  onco:related <https://onco.cc/cancers/basal-cell-carcinoma/>, <https://onco.cc/cancers/cutaneous-scc/>, <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/oncolytic-virus/>, <https://onco.cc/technologies/tcr-t/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/ctla4/> ;
  onco:drugs <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/retifanlimab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/talimogene-laherparepvec/> ;
  onco:companies <https://onco.cc/companies/merck/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/incyte/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/neonc-technologies/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:terms <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/irae/>, <https://onco.cc/terms/mcpyv-status/> ;
  onco:trials <https://onco.cc/trials/nct06947928/>, <https://onco.cc/trials/stamp-merkel/>, <https://onco.cc/trials/checkmate-358/> ;
  onco:pipeline <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/retifanlimab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:standardOfCare <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/retifanlimab/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/talimogene-laherparepvec/> .